Loading…
Loading…
EQUITY / NASDAQ · XNCM
Biodexa Pharmaceuticals plc ADR
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →01/01/2025 – 12/31/2025 · GBP · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.6199 USD · 0%
Observed: Oct 2, 2026, 11:10 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 0.6199 USD · Volume 185,431
251 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
4 available financial reports
Research reports →SEC FINANCIAL REPORTS
01/01/2025 – 12/31/2025 · Units
| Metric | 2025 / Year end | 2024 / Year end | Change |
|---|---|---|---|
| Operating profit | -8,645,000 GBP | -9,199,000 GBP | — |
| Net income | -6,384,000 GBP | -5,729,000 GBP | — |
| Operating cash flow | -5,591,000 GBP | -12,261,000 GBP | — |
| Cash and cash equivalents | 8,534,000 GBP | 1,669,000 GBP | +411.32% |
| Total liabilities | 6,774,000 GBP | 6,458,000 GBP | +4.89% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · GBP | 2024 / Year end01/01/2024 – 12/31/2024ConsolidatedUnits · GBP | 2024 / Year end04/25/2024 – 04/25/2024ConsolidatedUnits · GBP | 2023 / Year end01/01/2023 – 12/31/2023ConsolidatedUnits · GBP |
|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 8,534,000 GBP | 1,669,000 GBP | — | 5,971,000 GBP |
| Financing cash flowCash flow statement | 13,039,000 GBP | 8,557,000 GBP | — | 10,226,000 GBP |
| Investing cash flowCash flow statement | -583,000 GBP | -598,000 GBP | — | -265,000 GBP |
| Net incomeIncome statement | -6,384,000 GBP | -5,729,000 GBP | — | -7,079,000 GBP |
| Operating cash flowCash flow statement | -5,591,000 GBP | -12,261,000 GBP | — | -6,826,000 GBP |
| Operating profitIncome statement | -8,645,000 GBP | -9,199,000 GBP | — | -8,014,000 GBP |
| Total assetsBalance sheet | 18,179,000 GBP | 14,780,000 GBP | — | 10,542,000 GBP |
| Total equityBalance sheet | 11,405,000 GBP | 8,322,000 GBP | — | 4,678,000 GBP |
| Total liabilitiesBalance sheet | 6,774,000 GBP | 6,458,000 GBP | 3,100,000 GBP | 5,864,000 GBP |
| RevenueIncome statement | — | — | — | 381,000 GBP |
| Report source | Open report ↗ Published: 03/27/2026 | Open report ↗ Published: 03/27/2026 | Open report ↗ Published: 04/11/2025 | Open report ↗ Published: 03/27/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.